Publication: Thyroid eye disease: Redefining its management—A review
| dc.contributor.author | Amy P. Jain | en_US |
| dc.contributor.author | Pimkwan Jaru-Ampornpan | en_US |
| dc.contributor.author | Raymond S. Douglas | en_US |
| dc.contributor.other | Siriraj Hospital | en_US |
| dc.contributor.other | Cedars-Sinai Medical Center | en_US |
| dc.date.accessioned | 2022-08-04T10:59:36Z | |
| dc.date.available | 2022-08-04T10:59:36Z | |
| dc.date.issued | 2021-03-01 | en_US |
| dc.description.abstract | Thyroid eye disease (TED) is a debilitating, vision threatening disease that dramatically alters patients' quality of life. Until recently, the management of TED is a long arduous course with supportive therapy, followed by an extensive surgical treatment plan to reverse the disease endpoints. Teprotumumab offers an early, safe therapeutic intervention to help reverse disease end points such as diplopia and proptosis and improve quality of life. | en_US |
| dc.identifier.citation | Clinical and Experimental Ophthalmology. Vol.49, No.2 (2021), 203-211 | en_US |
| dc.identifier.doi | 10.1111/ceo.13899 | en_US |
| dc.identifier.issn | 14429071 | en_US |
| dc.identifier.issn | 14426404 | en_US |
| dc.identifier.other | 2-s2.0-85100471722 | en_US |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/78407 | |
| dc.rights | Mahidol University | en_US |
| dc.rights.holder | SCOPUS | en_US |
| dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85100471722&origin=inward | en_US |
| dc.subject | Medicine | en_US |
| dc.title | Thyroid eye disease: Redefining its management—A review | en_US |
| dc.type | Review | en_US |
| dspace.entity.type | Publication | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85100471722&origin=inward | en_US |